| Management target | Revenue 11.0% FY27 |
|---|
| Revenue growth | 6.4% YoY |
|---|---|
| Margins | EBITDA margin at 36.6% (up 650 bps YoY) |
| Demand visibility | Strong momentum across geographies in non-GPL portfolio |
| Management confidence | High; confident in momentum sustainability |
Growth
Revenue grew 6.4% YoY, while EBITDA and PAT grew 29.1% and 31.8% YoY respectively. Non-GPL business grew 26.5% YoY.
Outlook
Management guides 10-12% revenue growth for FY27 with 30-32% EBITDA margins. Significant 465 KL greenfield expansion underway at Solapur.
Risks
GPL business declined 52.6% YoY due to inventory rationalization; ongoing geopolitical uncertainties noted in regulated markets.
Last quarter's promises, checked
Delivered
- EBITDA Margin 30-32% → delivered 36.6% (= BEAT)
- Revenue Growth 5.7% CAGR (FY24-26) → delivered 6.4% YoY (= BEAT)
- Solapur Phase 1 operational Q2 FY27 → delivered on track (= BEAT)
Partly delivered
- CDMO 2 contracts in early H2 FY27 → delivered 3.8% growth (= PARTIAL)
Investor Presentation filed with NSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹16,766 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.8×Sector 50.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
- Call
- Guides 11% growth
Alivus Life Sciences Q1 FY27 Results: Net Profit ₹160.1 Cr, Up 31.8% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹160.1 Cr · +31.8% YoY
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.